Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Biotech
Henlius carves out $440M T-cell engager deal with Amberstone
Fosun Pharma subsidiary Henlius Biotech has signed a $440 million deal with California-based Amberstone Biosciences to work on T-cell engagers.
James Waldron
Sep 24, 2026 10:02am
Acadia misses mark in Alzheimer’s but continues phase 3 program
Sep 24, 2026 9:46am
Merck sees pivotal victory for $3B eye disease prospect
Sep 24, 2026 8:15am
Kyverna pubs 1-year miv-cel data as CAR-T peers hit safety snags
Sep 24, 2026 6:02am
Eli Lilly puts up $100M for 5-target deal with China's InnoCare
Sep 24, 2026 2:39am
Immunovant ends cutaneous lupus program after phase 2 flop
Sep 23, 2026 8:59am
